+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' Property and difference as bile acids



Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' Property and difference as bile acids



Hepatology Research 33(2): 174-177



Ursodeoxycholic acid (UDCA) is a bile acid, which is present in human bile at a low concentration of only 3% of total bile acids. It is a 7beta-hydroxy epimer of the primary bile acid chenodeoxycholic acid (CDCA). UDCA is isolated from the Chinese drug 'Yutan' a powder preparation derived from the dried bile of adult bears. For centuries, Yutan has been used in the treatment of hepatobiliary disorders. In Japan, it has also been in widespread use as a folk medicine from the mid-Edo period. In Japan, not only basic studies such as isolation, crystallization, definition of the chemical structure and establishment of the synthesis of UDCA have been conducted but clinical studies have been conducted. First reports on the effects of UDCA in patients with liver diseases came from Japan as early as 1961. In the 1970s, the first prospective study of patients with gallbladder stones treated with UDCA demonstrating gallstone dissolution was reported. In late 1980s, a number of controlled trials on the use of UDCA in primary biliary cirrhosis (PBC) were reported. Since then, a variety of clinical studies have shown the beneficial effect of UDCA in liver disease worldwide. To date, UDCA is utilized for the treatment of PBC for which it is the only drug approved by the U.S. Food and Drug Administration (FDA). In recent years, with the advent of molecular tools, the mechanisms of action of bile acids and UDCA have been investigated, and various bioactivities and pharmacological effects have been revealed. Based on the results of these studies, the bioactive substances in bile acids that are involved in digestive absorption may play important roles in signal transduction pathways. Furthermore, the mechanisms of action of UDCA is evidently involved. We reveal the physicochemical properties of UDCA as bile acid and overview the established pharmacological effects of UDCA from its metabolism. Furthermore, we overview the current investigations into the mechanism of action of UDCA in liver disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012145055

Download citation: RISBibTeXText

PMID: 16214392

DOI: 10.1016/j.hepres.2005.09.029


Related references

Effect of ursodeoxycholic acid udca treatment on the biliary secretion of bile acids and bile lipids in primary sclerosing cholangitis psc. Gastroenterology 98(5 PART 2): A637, 1990

Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). Journal of Medicinal Chemistry 57(18): 7687-7701, 2014

Effects of ursodeoxycholic acid analogues of ursodeoxycholic acid and combination of bile acids on bile acid synthesis in cultured rat hepatocytes. Biochimica et Biophysica Acta 920(3): 195-204, 1987

Ursodeoxycholic acid udca inhibits the active absorption of bile acids ba in the terminal ileum of rat. Gastroenterology 100(5 PART 2): A790, 1991

Effects of lovastatin ls ursodeoxycholic acid udca and ls plus udca on bile lipid composition in patients with cholesterol ch gallstones. Gastroenterology 102(4 PART 2): A319, 1992

Tauroursodeoxycholic acid appears more effective than UDCA at displacing hydrophobic bile acids from the bile acid pool of patients with primary biliary cirrhosis. Hepatology 20(4 PART 2): 150A, 1994

Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Digestive Diseases and Sciences 41(12): 2417-2422, 1996

A study on size of molecular aggregates formed by bile acid in human gallbladder bile with special reference to comparison of chenodeoxycholic acid rich bile and ursodeoxycholic acid rich bile. Hirosaki Medical Journal 39(3): 414-426, 1987

A study on size of molecular aggregates formed by bile acid in human gallbladder bile with special reference to comparison of bile with chenodeoxycholic acid treatment and bile with ursodeoxycholic acid treatment. Japanese Journal of Gastroenterology 84(6): 1289-1294, 1987

Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology 78(2): 214-219, 1980

A study on the size of molecular aggregates formed by bile acid in human gallbladder bile: with special reference to a comparison of bile treated with chenodeoxycholic acid and with ursodeoxycholic acid. Nihon Shokakibyo Gakkai Zasshi 84(6): 1289-1294, 1987

Effect of ursodeoxycholic acid udca on hepatic bile acid handling in primary biliary cirrhosis pbc. Clinical Science (London) 82(3): 24P-25P, 1992

Influence of ursodeoxycholic acid udca on bile acid metabolism of patients with primary biliary cirrhosis pbc. Gastroenterology 98(5 PART 2): A590, 1990

Correcting biliary phenotype in cystic fibrosis mice Nor-ursodeoxycholic acid , but not UDCA, normalizes hepatic bile pH and increases bile flow in G551D CF mice. Hepatology 36(4 Part 2): 337A, October, 2002

Ursodeoxycholic acid udca improves hepatic bile acid transit and excretion in primary biliary cirrhosis pbc. Gastroenterology 100(5 PART 2): A756, 1991